Home / Resource Library / Cost impact of Brutons tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

Cost impact of Brutons tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

Study examined cost effectiveness of BTK inhibitors in treatment of CLL.